Uramoto H - Search Results

1

Resistance to gefitinib.

Uramoto H, Sugio K, Oyama T, Sugaya M, Hanagiri T, Yasumoto K. Uramoto H, et al. Int J Clin Oncol. 2006 Dec;11(6):487-91. doi: 10.1007/s10147-006-0609-y. Epub 2006 Dec 25. Int J Clin Oncol. 2006. PMID: 17180521

2

Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients.

Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T, Yoshino I, Nakanishi R, Ichiyoshi Y, Yasumoto K. Uramoto H, et al. Eur J Cancer. 1999 Oct;35(10):1462-5. doi: 10.1016/s0959-8049(99)00157-4. Eur J Cancer. 1999. PMID: 10673978

3

Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.

Hosomi Y, Ohe Y, Mito K, Uramoto H, Moriyama E, Tanaka K, Kodama K, Niho S, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Kakinuma R, Nishiwaki Y. Hosomi Y, et al. Among authors: uramoto h. Jpn J Clin Oncol. 1999 Nov;29(11):546-9. doi: 10.1093/jjco/29.11.546. Jpn J Clin Oncol. 1999. PMID: 10678557 Clinical Trial.

4

Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.

Oyama T, Osaki T, Nose N, Ichiki Y, Inoue M, Imoto H, Yoshimatsu T, Kodate M, Uramoto H, Mizoue T, Yano K, Yasumoto K. Oyama T, et al. Among authors: uramoto h. Anticancer Res. 2000 Jan-Feb;20(1B):505-10. Anticancer Res. 2000. PMID: 10769714

5

Prediction of pulmonary complications after a lobectomy in patients with non-small cell lung cancer.

Uramoto H, Nakanishi R, Fujino Y, Imoto H, Takenoyama M, Yoshimatsu T, Oyama T, Osaki T, Yasumoto K. Uramoto H, et al. Thorax. 2001 Jan;56(1):59-61. doi: 10.1136/thorax.56.1.59. Thorax. 2001. PMID: 11120906 Free PMC article.

6

Benign mesenchymoma of the mediastinum.

Uramoto H, Oyama T, Yoshimatsu T, Osaki T, Yasumoto K. Uramoto H, et al. Jpn J Thorac Cardiovasc Surg. 2000 Dec;48(12):814-6. doi: 10.1007/BF03218258. Jpn J Thorac Cardiovasc Surg. 2000. PMID: 11197828 Review.

7

Aggressive surgical treatment of multiple primary lung cancers.

Uramoto H, Nakanishi R, Osaki T, Yoshino I, Yasumoto K. Uramoto H, et al. Scand Cardiovasc J. 2000 Dec;34(6):603-5. doi: 10.1080/140174300750064567. Scand Cardiovasc J. 2000. PMID: 11214016

8

[Treatment and results of interstitial lung diseases in video assisted thoracoscopic lung biopsy].

Uramoto H, Osaki T, Nose N, Ichiki Y, Imoto H, Yoshimatsu T, Oyama T, Yasumoto K. Uramoto H, et al. J UOEH. 2001 Mar 1;23(1):45-50. doi: 10.7888/juoeh.23.45. J UOEH. 2001. PMID: 11279840 Japanese.

9

Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy.

Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M, Kohno K. Torigoe T, et al. Among authors: uramoto h. Anticancer Drugs. 2002 Mar;13(3):237-43. doi: 10.1097/00001813-200203000-00005. Anticancer Drugs. 2002. PMID: 11984067 Review.

10

Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents.

Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K. Torigoe T, et al. Among authors: uramoto h. J Biol Chem. 2002 Sep 27;277(39):36534-43. doi: 10.1074/jbc.M202605200. Epub 2002 Jul 19. J Biol Chem. 2002. PMID: 12133827

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results